Natco Pharma is currently trading at Rs. 562.00, up by 2.60 points or 0.46% from its previous closing of Rs. 559.40 on the BSE.
The scrip opened at Rs. 562.80 and has touched a high and low of Rs. 567.05 and Rs. 562.00 respectively. So far 136 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 750.00 on 19-Nov-2018 and a 52 week low of Rs. 482.00 on 28-May-2019.
Last one week high and low of the scrip stood at Rs. 585.85 and Rs. 541.50 respectively. The current market cap of the company is Rs. 10174.78 crore.
The promoters holding in the company stood at 48.9%, while Institutions and Non-Institutions held 30.56% and 20.47% respectively.
Natco Pharma has commenced commercial operations at Finished Dosage Formulations (FDF) facility in Visakhapatnam. The facility is a part of the Special Economic Zone (SEZ) and intended to cater primarily to the US & other international markets.
Vizag facility is a key part of Natco Pharma’s capacity expansion plans for its pipeline of products and diversification into different geographies. From capability perspective, this facility will focus mostly on oral solid dosages (tablets and capsules), including a cytotoxic block for products in the oncology segment. An application with the US Food and Drug Administration (USFDA) is already filed for site transfer of the first product & to trigger a regulatory audit.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.